Despite intense efforts, Alzheimer’s disease (AD) is one of the top public health crisis for society even at 21st century. Since presently there is no cure for AD, early diagnosis of possible AD biomarkers is crucial for the society. Driven by the need, the current manuscript reports the development of magnetic core-plasmonic shell nanoparticle attached hybrid graphene oxide based multifunctional nanoplatform which has the capability for highly selective separation of AD biomarkers from whole blood sample, followed by label-free surface enhanced Raman spectroscopy (SERS) identification in femto gram level. Experimental ELISA data show that antibody-conjugated nanoplatform has the capability to capture more than 98% AD biomarkers from the whole blood sample. Reported result shows that nanoplatform can be used for SERS “fingerprint” identification of β-amyloid and tau protein after magnetic separation even at 100 fg/mL level. Experimental results indicate that very high sensitivity achieved is mainly due to the strong plasmon-coupling which generates huge amplified electromagnetic fields at the “hot spot”. Experimental results with nontargeted HSA protein, which is one of the most abundant protein components in cerebrospinal fluid (CSF), show that multifunctional nanoplatform based AD biomarkers separation and identification is highly selective.
According to the World Health Organization, even in the 21st century, more than one million children die each year due to the rotavirus contamination of drinking water. Therefore, accurate identification and removal of rotavirus are very important to save childrens' lives. Driven by the need, in this Letter, we report for the first time highly selective identification and removal of rotavirus from infected water using a bioconjugated hybrid graphene oxide based three-dimensional (3D) solid architecture. Experimental results show that due to the presence of a high intensity of "hot spots" in the 3D network, an antibody-attached 3D plasmonic-magnetic architecture can be used for accurate identification of rotavirus using surface-enhanced Raman spectroscopy (SERS). Reported data demonstrate that the antibody-attached 3D network binds strongly with rotavirus and is capable of highly efficient removal of rotavirus, which has been confirmed by SERS, fluorescence imaging, and enzyme-linked immunosorbent assay (ELISA) data. We discuss a possible mechanism for accurate identification and efficient removal of rotavirus from infected drinking water.
Circulating tumor cells (CTCs) are
extremely rare cells in blood containing billions of other cells.
The selective capture and identification of rare cells with sufficient
sensitivity is a real challenge. Driven by this need, this manuscript
reports the development of a multifunctional biocompatible graphene
oxide quantum dots (GOQDs) coated, high-luminescence magnetic nanoplatform
for the selective separation and diagnosis of Glypican-3 (GPC3)-expressed
Hep G2 liver cancer tumor CTCs from infected blood. Experimental data
show that an anti-GPC3-antibody-attached multifunctional nanoplatform
can be used for selective Hep G2 hepatocellular carcinoma tumor cell
separation from infected blood containing 10 tumor cells/mL of blood
in a 15 mL sample. Reported data indicate that, because of an extremely
high two-photon absorption cross section (40530 GM), an anti-GPC3-antibody-attached
GOQDs-coated magnetic nanoplatform can be used as a two-photon luminescence
platform for selective and very bright imaging of a Hep G2 tumor cell
in a biological transparency window using 960 nm light. Experimental
results with nontargeted GPC3(−) and SK-BR-3 breast cancer
cells show that multifunctional-nanoplatform-based cell separation,
followed by two-photon imaging, is highly selective for Hep G2 hepatocellular
carcinoma tumor cells.
Cancer, a life-threatening disease, has become a global pandemic. Targeted tumor imaging using near-infrared (NIR) light is the key to improve the penetration depth and it is highly promising for clinical tumor diagnostics. Driven by this need, in this Letter we have reported aptamer conjugated graphene oxide-based two-photon imaging of breast tumor cells selectively. Reported data indicate that there is an extremely high two-photon absorption from aptamer conjugated graphene oxide (σ2PA = 46890 GM). Experimental data show that two-photon luminescence signal remains almost unchanged even after 2 h of illuminations. Reported results show that S6 RNA aptamers conjugated graphene oxide-based two-photon fluorescence can be used for selective two-photon imaging of SK-BR-3 breast tumor cell in second biological transparency windows using 1100 nm wavelength. Experimental data demonstrate that it is highly capable of distinguishing targeted breast cancer SK-BR-3 cells from other nontargeted MDA-MB-231 breast cancer cells.
Circulating
tumor cells (CTC) are highly heterogeneous in nature
due to epithelial–mesenchymal transition (EMT), which is the
major obstacle for CTC analysis via “liquid biopsy”.
This article reports the development of a new class of multifunctional
fluorescent–magnetic multicolor nanoprobes for targeted capturing
and accurate identification of heterogeneous CTC. A facile design
approach for the synthesis and characterization of bioconjugated multifunctonal
nanoprobes that exhibit excellent magnetic properties and emit very
bright and photostable multicolor fluorescence at red, green, and
blue under 380 nm excitation is reported. Experimental data presented
show that the multifunctional multicolor nanoprobes can be used for
targeted capture and multicolor fluorescence mapping of heterogeneous
CTC and can distinguish targeted CTC from nontargeted cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.